BETi/HDACi treatment of CTCL cells induces significant alterations of transcripts regulating CTCL apoptosis

Based on our prior efficacy and toxicity studies, we selected 125nM birabresib (OTX015) (BETi) and 1nM romidepsin (HDACi) for all experiments in this report (Zhao et al., 2019). Gene expression was analyzed in triplicate on HH, Hut78, MyLa, SeAx and SZ4 CTCL lines at 0, 6, 48 and 96 hours post-treatment and normalized to housekeeping genes. Analysis was enriched for pro- and anti-apoptotic, oncogenic and tumor suppressor genes.

Reference
Zhao L, Ohkovat J-P, Hong EK, Kim YH, Wood GS. Preclinical studies support combined inhibition of BET family proteins and histone deacetylases as epigenetic therapy for cutaneous T-cell lymphoma. Neoplasia 21: 82-92, 2019.